Q1 2026 Group performance Comparable order intake growth 6% Group sales of EUR 3.9 billion, reflecting 4% increase in comparable sales Income from operations increased to EUR 241 million Adjusted EBITA margin increased 40 basis points to 9.0%... Read more
As biologics manufacturing operations become increasingly complex, biopharma companies are under growing pressure to improve efficiency, strengthen contamination control and meet evolving regulatory expectations without compromising product q... Read more
As pharmaceutical companies continue to face high attrition rates, rising development costs and increasingly complex clinical datasets, the industry is searching for more predictive approaches to drug discovery and development. In this exclusive Q&am... Read more
Fluid overload remains one of the most complex and costly challenges in cardiorenal care, particularly for patients who no longer respond to conventional diuretic therapies. As healthcare systems increasingly prioritize precision medicine, proactive ... Read more
Highly potent drugs now account for over 30% of the global pipeline, with more than 1,000 molecules in development — Axplora’s investments in HPAPI capacity help customers bring these complex therapies to market faster $60 ... Read more
Expands Agilent’s pathology portfolio through addition of highly complementary antibody, reagent and instrument business with annual double-digit revenue and profit growth since 2021 Expected to be accretive to Agilent’s top-line gro... Read more
Hongene Biotech Corporation today announced its support of SiranBio’s SA1211 program, a dual-target siRNA candidate for chronic hepatitis B, underscoring Hongene’s ability to deliver end-to-end development and manufacturing solutions fo... Read more
WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that three of its manufacturing facilities in Wuxi – Drug Substance Facility 5 (MFG5), Drug Product Facility 2 ... Read more
© 2026 Biopharma Boardroom. All Rights Reserved.
